Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes

American Journal of Transplantation

Volumn 12, Issue 6, 2012, Pages 1576-1583

  Bellin, M D ^a   Barton, F B ^b   Heitman, A ^b   Harmon, J V ^a   Kandaswamy, R ^a   Balamurugan, A N ^a   Sutherland, D E R ^a   Alejandro, R ^c   Hering, B J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b EMMES CORPORATION   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Alemtuzumab; antithymocyte globulin; CD3; islet transplant; OKT3; T cell

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; DACLIZUMAB; EFALIZUMAB; ETANERCEPT; INSULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; TEPLIZUMAB; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOTHERAPY; ISLETS OF LANGERHANS TRANSPLANTATION;

EID: 84861792224     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03977.x     Document Type: Article

References (42)

1. Cryer PE,. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57: 3169-3176.
2. Ryan EA, Paty BW, Senior PA, et al,. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-2069.
3. Shapiro AM, Ricordi C, Hering BJ, et al,. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318-1330.
4. Robertson RP., Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes 2010; 59: 1285-1291.
5. Shapiro AM, Lakey JR, Ryan EA, et al,. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
6. Monti P, Scirpoli M, Maffi P, et al,. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 2008; 118: 1806-1814.
7. Nir T, Melton DA, Dor Y., Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007; 117: 2553-2561.
8. Keymeulen B, Korbutt G, De Paepe M, Gorus F, Kloppel G, Pipeleers DG., Long-term metabolic control by rat islet grafts depends on the composition of the implant. Diabetes 1996; 45: 1814-1821.
9. Hering BJ, Kandaswamy R, Harmon JV, et al,. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004; 4: 390-401.
10. Hering BJ, Kandaswamy R, Ansite JD, et al,. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293: 830-835.
11. Rickels MR, Chiou AJ, Fuller C, et al,. Beta-cell secretory capacity after human islet transplantation by the CIT07 versus Edmonton protocol: Preliminary results. Am J Transplant 2011; 11 (Suppl 2): 79-80.
12. Maki T, Ichikawa T, Blanco R, Porter J., Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci USA 1992; 89: 3434-3438.
13. Chatenoud L., Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol 2010; 6: 149-157.
14. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al,. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-2608.
15. Herold KC, Gitelman S, Greenbaum C, et al,. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009; 132: 166-173.
16. Bellin MD, Kandaswamy R, Parkey J, et al,. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 2008; 8: 2463-2470.
17. -2010 Annual Data Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD.
18. Westermark GT, Westermark P, Berne C, Korsgren O, Nordic Network for Clinical Islet Transplantation. Widespread amyloid deposition in transplanted human pancreatic islets. N Engl J Med 2008; 359: 977-979.
19. Huurman VA, Hilbrands R, Pinkse GG, et al,. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One 2008; 3: e2435.
20. Smith RN, Kent SC, Nagle J, et al,. Pathology of an islet transplant 2 years after transplantation: Evidence for a nonimmunological loss. Transplantation 2008; 86: 54-62.
21. Prentki M, Nolan CJ., Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116: 1802-1812.
22. Bonora E., Protection of pancreatic beta-cells: Is it feasible? Nutr Metab Cardiovasc Dis 2008; 18: 74-83.
23. Alejandro R, Cutfield RG, Shienvold FL, et al,. Natural history of intrahepatic canine islet cell autografts. J Clin Invest 1986; 78: 1339-1348.
24. Sutherland DE, Radosevich D, Bland B, et al,. Total pancreatectomy and islet autotransplant for chronic pancreatitis: Early outcomes in recent cases. [Abstract]. Pancreas 2009; 38: 1051.
25. Warnock GL, Kneteman NM, Ryan E, Seelis RE, Rabinovitch A, Rajotte RV., Normoglycaemia after transplantation of freshly isolated and cryopreserved pancreatic islets in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1991; 34: 55-58.
26. Gangemi A, Salehi P, Hatipoglu B, et al,. Islet transplantation for brittle type 1 diabetes: The UIC protocol. Am J Transplant 2008; 8: 1250-1261.
27. Vendrame F, Pileggi A, Laughlin E, et al,. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010; 59: 947-957.
28. Naji A, Silvers WK, Bellgrau D, Barker CF., Spontaneous diabetes in rats: Destruction of islets is prevented by immunological tolerance. Science 1981; 213: 1390-1392.
29. Bartlett ST, Chin T, Dirden B, Quereshi A, Hadley G., Inclusion of peripancreatic lymph node cells prevents recurrent autoimmune destruction of islet transplants: Evidence of donor chimerism. Surgery 1995; 118: 392-397; Discussion 397-398.
30. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al,. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 2010; 33: 826-832.
31. van de Linde P, Vd Boog PJ, Tysma OM, et al,. Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin. Clin Exp Immunol 2007; 149: 56-62.
32. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC,. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005; 115: 2904-2913.
33. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N., A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006; 17: 2844-2853.
34. Gurkan S, Luan Y, Dhillon N, et al,. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010; 10: 2132-2141.
35. Sewgobind VD, van der Laan LJ, Kho MM, et al,. The calcineurin inhibitor tacrolimus allows the induction of functional CD4CD25 regulatory T cells by rabbit anti-thymocyte globulins. Clin Exp Immunol 2010; 161: 364-377.
36. Toso C, Edgar R, Pawlick R, et al,. Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transpl Int 2009; 22: 182-191.
37. Rabinovitch A, Sumoski W, Rajotte RV, Warnock GL,. Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture. J Clin Endocrinol Metab 1990; 71: 152-156.
38. Lai Y, Chen C, Linn T., Innate immunity and heat shock response in islet transplantation. Clin Exp Immunol 2009; 157: 1-8.
39. Ishii D, Schenk AD, Baba S, Fairchild RL., Role of TNFalpha in early chemokine production and leukocyte infiltration into heart allografts. Am J Transplant 2010; 10: 59-68.
40. Hardinger KL., Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy 2006; 26: 1771-1783.
41. Yang XD, Tisch R, Singer SM, et al,. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice: I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994; 180: 995-1004.
42. Wu AJ, Hua H, Munson SH, McDevitt HO., Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci USA 2002; 99: 12287-12292.